NewsRx

Search our medical news database

Anterior Uveitis News and Articles

Return to Library

Recent Anterior Uveitis News and Articles


Data on Cardiovascular Research Described by Researchers at Virginia University Medical Center

2012 DEC 31 (NewsRx) -- By a News Reporter-Staff News Editor at Cardiovascular Week -- Investigators publish new report on Cardiovascular Research. According to news reporting originating in Amsterdam, Netherlands, by NewsRx journalists, research stated, "Spondyloarthritis (SpA) is a chronic inflammatory disease with either predominantly axial symptoms of the spine and sacroiliac joints (axial SpA, including ankylosing spondylitis) or predominantly arthritis (peripheral SpA). Next to these spinal and articular symptoms, many patients with SpA also have extra-articular manifestations (EAMs)."

The news reporters obtained a quote from the research from Virginia University Medical Center, "EAMs associated with SpA include anterior uveitis (25-30%), psoriasis (10-25%) or inflammatory bowel disease (IBD) (5-10%) and cardiovascular manifestations. Peripheral arthritis occurs in approximately 30% of patients, especially in large joints, and shows an asymmetrical, oligoarticular pattern. Other common joint complaints are due to enthesitis, which manifest as extra-articular bony tenderness in areas such as the Achilles tendon. Acute anterior uveitis presents with acute pain, loss of vision and redness in one eye that usually subsides spontaneously after several weeks. Rapid treatment by an ophthalmologist is required to prevent synechiae formation which could ultimately result in glaucoma and blindness. Although less common, organ involvement in SpA can also be located in the heart, lungs or kidneys. The risk of cardiovascular events is increased in SpA. Cardiac manifestations can involve the aortic valve (1-10%) or the atrioventricular node and the risk of atherosclerotic events is increased in this group. Treatment of SpA includes physical exercise and nonsteroidal anti-inflammatory drugs (NSAIDs), and in case of peripheral arthritis, sulphasalazine can be added. When there is insufficient response to NSAIDs, tumor necrosis factor blockers, especially infliximab, etanercept, adalimumab and golimumab, are very effective in treating axial manifestations, arthritis, enthesitis and psoriasis. Anterior uveitis in SpA can be treated adequately by the ophthalmologist and in the case of refractory uveitis, treatment with adalimumab and infliximab seems to be more effective compared with etanercept. When IBD occurs with SpA, the use of NSAIDs should be minimized, except for celecoxib, and infliximab or adalimumab are preferred to etanercept. The incidence of atherosclerotic events or SpA-specific cardiac manifestations may be decreased by cardiovascular risk management or effective antirheumatic treatment."

According to the news reporters, the research concluded: "Overall it is important to realize that extra-articular manifestations frequently occur in patients with SpA and should be taken into account in the choice of treatment."

For more information on this research see: Management and evaluation of extra-articular manifestations in spondyloarthritis. Therapeutic Advances In Musculoskeletal Disease, 2012;4(6):413-22. (Sage Publications - www.sagepub.com/; Therapeutic Advances In Musculoskeletal Disease - tab.sagepub.com)

Our news correspondents report that additional information may be obtained by contacting I.E. van der Horst-Bruinsma, VU University Medical Center, Room 3A-64, PO Box 7057, 1007 MB Amsterdam, Netherlands.

Keywords for this news article include: Europe, Amsterdam, Arthritis, Cardiology, Netherlands, Eye Diseases, Ophthalmology, Joint Diseases, Uveal Diseases, Anterior Uveitis, Cardiovascular Research, Musculoskeletal Diseases.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2012, NewsRx LLC

NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook